| Outcome Measures: |
Primary: Changes in glycosylated hemoglobin (HbA1c) from baseline to week 20, Baseline through Day 141 (the end of the 20-week treatment) | Secondary: Change in body weight from baseline to week 20, Baseline through Day155 (the end of the follow-up)|Change in body mass index (BMI) from baseline to week 20, Baseline through Day155 (the end of the follow-up)|Change in waist circumference from baseline to week 20, Baseline through Day155 (the end of the follow-up)|Change in waist-hip ratio from baseline to week 20, Baseline through Day155 (the end of the follow-up)|Change in blood pressure(systolic and diastolic blood pressure) from baseline to week 20, Baseline through Day155 (the end of the follow-up)|Change in blood lipid from baseline to week 20, Baseline through Day155 (the end of the follow-up)|Proportion of subjects with a baseline weight loss of more than 5%, Baseline through Day155 (the end of the follow-up)|Incidence of adverse events, Baseline through Day155 (the end of the follow-up)|Minimum steady-state plasma drug concentration during a dosage interval (Cmin, SS), Day1, 29, 57, 85 and 113|Change in fasting blood glucose from baseline to week 20, Baseline through Day 141 (the end of the 20-week treatment)|Change in 2-hour postprandial blood glucose from baseline to week 20, Baseline through Day 141 (the end of the 20-week treatment)|The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (Nab)., Day1, 29, 57, 85, 113 and 155
|
